RDUS (Radius Pharmaceuticals) Earnings growth in current year

RDUS (Radius Pharmaceuticals) - company brandmark

Reliable raw material supply contracts for metabolic developments minimize logistical risks for Radius Recycling, Inc. (RDUS). The annual net income per share growth rate reflects current market sensitivity, where the -5.80 mark indicates the current yield level. Fundamentals rely on the patent protection of the drug TYMLOS for the treatment of osteoporosis and stable revenue from scrap metal recycling, which depends on steel prices.

RDUS: Radius Recycling, Inc. Earnings per share growth in current year 07/04/2022 - 07/26/2025

Financial and market metric breakdowns for Radius Recycling Inc. (RDUS)

- share price and expert price forecast:
Basic company analysis:RDUS - Radius Pharmaceuticals
Finished products of Radius Recycling

The long-term sustainability of Radius Recycling, Inc. (RDUS) is determined by its ability to generate real capital growth per share. This percentage change in earnings per share compared to last year measures net income dynamics, allowing investors to assess margin management efficiency and the impact of share buybacks. Stable funding for advanced research in metabolic osteoporosis therapy confirms the availability of resources to maintain this positive momentum.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio Pharma|Agios Corp (AGIO) - Expected net earnings per share growth this year|Earnings per share growth in current year structuretx.com (GPCR)|Net earnings per share growth this year mimedx.com MDXG|Earnings per share growth in current year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Earnings per share growth in current year|MBX: Net earnings per share growth this year|Altimmune Corp - Net earnings per one share growth for the current year|Aardvark Therapeutics Inc (AARD) - Earnings per share growth in current year|Net earnings per share change in current year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth in current year|Net earnings per share growth this year Biomea Fusion (BMEA)|Earnings growth in current year QNCX|Net earnings per one share growth for the current year GUTS|Earnings growth in current year VTVT (vTv Therapeutics Inc.)|Earnings per share increase in current year ATPC|Pluristem Therapeutics - Earnings growth in current year|Expected net earnings per share growth this year synlogictx.com SYBX|LPCN: Earnings growth in current year|Matinas BioPharma Holdings, Inc. - Earnings per share increase in current year|SPRB (Spruce Biosciences Inc.) - Earnings growth in current year|galecto.com (GLTO) - Expected net earnings per share growth this year|Earnings per share growth in current year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Earnings per share increase in current year|Earnings per share growth in current year organovo.com ONVO